Trelagliptin 50mg Tablet PCD Company in Gujarat

Trelanip 50 Tablet Franchise Supplier in Rajasthan

Trelagliptin 50mg Tablet Manufacturer in Himachal Pradesh

Best PCD Pharma for Trelanip 50 Tablet in Maharashtra

Trelagliptin Tablet 50mg Third Party Manufacturer in Uttarakhand
Trelagliptin 50mg Tablets Exporter from India

Home/Products /trelagliptin-50mg-tablet

About the Product

Description


Trelanip 50 Tablet contains Trelagliptin 50mg, a long-acting oral antidiabetic agent from the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class. It works by enhancing the activity of incretin hormones, which leads to an increase in insulin secretion and a decrease in glucagon release, especially after meals. This helps in lowering blood glucose levels in patients with type 2 diabetes mellitus. Trelagliptin stands out from other DPP-4 inhibitors due to its once-weekly dosing, offering convenience and better adherence to therapy. It generally has a neutral effect on body weight and carries a low risk of hypoglycemia when used as monotherapy.

Commonly reported side effects include nasopharyngitis, headache, upper respiratory tract infections, and mild gastrointestinal discomfort. While rare, hypoglycemia may occur, particularly when used with insulin or insulin secretagogues like sulfonylureas. Occasional allergic skin reactions such as rashes have also been reported.

Trelanip 50 is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control as an adjunct to diet and exercise. It can be used alone or in combination with other antidiabetic medications such as metformin, sulfonylureas, or thiazolidinediones when monotherapy does not provide adequate glycemic control.

Trelanip 50 should be used only under the supervision of a healthcare professional, especially in patients with moderate to severe renal or hepatic impairment. It is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Blood glucose levels should be monitored regularly during treatment.

Store in a cool and dry place below 25°C, away from moisture, heat, and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Trelagliptin 50mg Tablet in the PCD pharma franchise market?

Trelagliptin 50mg Tablet has growing demand in the diabetology, endocrinology, general medicine, and chronic care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on innovative anti-diabetic and specialty pharmaceutical portfolios.

Why should medical distributors include Trelagliptin 50mg Tablet in their product range?

Medical distributors and agencies can benefit from increasing demand for Type 2 diabetes management under healthcare professional supervision. Trelagliptin 50mg is a DPP-4 (dipeptidyl peptidase-4) inhibitor that helps improve glycemic control by increasing endogenous incretin hormone activity, thereby enhancing glucose-dependent insulin secretion and reducing glucagon secretion Commonly prescribed as an adjunct to diet and exercise for the management of Type 2 Diabetes Mellitus in adults, as advised by healthcare professionals and approved prescribing information Features a once-weekly oral dosing regimen, offering convenience that may improve treatment adherence in appropriate patients May be prescribed as monotherapy or in combination with other oral antidiabetic agents or insulin, depending on the patient's clinical needs and treatment goals Should be used under medical supervision with regular monitoring of blood glucose and HbA1c, along with lifestyle modifications including a healthy diet and regular physical activity. It is not indicated for Type 1 diabetes mellitus or diabetic ketoacidosis Frequently utilized in diabetology clinics, endocrinology practices, general medicine departments, and chronic disease management programs Widely prescribed by diabetologists, endocrinologists, and general physicians for appropriate patients with Type 2 diabetes This strengthens a comprehensive anti-diabetic and chronic care portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Trelagliptin 50mg Tablet?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Trelagliptin 50mg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from growing demand in the diabetes care market, increasing acceptance of innovative once-weekly oral therapies, reliable supply chain support, repeat prescriptions, and attractive margins in the chronic care segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, wholesalers, and institutional suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality anti-diabetic products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.